IRWD FINANCIAL STATEMENTS

Ironwood Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

IRWDIronwood Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue361.5 M $+13.8%

Gross Profit360.1 M $+38.3%

Operating Income201.8 M $+280.9%

EBITDA207.1 M $+167.4%

Net Income102.2 M $—

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
IRWD	13.8%	99.6%	57.3%	28.3%
GENIL	16.3%	23.4%	14.3%	4.0%
ECILC	-2.3%	34.3%	14.8%	-3.6%
HLN	-26.7%	61.5%	25.2%	12.6%
BHC	-9.9%	75.9%	60.0%	-13.5%
TLRY	3.8%	27.7%	-156.2%	-158.8%
Industry median	7.5%	60.6%	18.2%	4.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
IRWD	13.8%	99.6%	57.3%	28.3%
AMPH	-1.1%	47.3%	26.6%	11.0%
PCRX	4.6%	79.3%	16.1%	0.7%
EBS	-29.9%	44.4%	22.8%	-1.3%
EOLS	9.6%	65.5%	-4.6%	-14.4%
PAHC	26.0%	32.5%	15.0%	6.3%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Current Liabilities236.3 M $36%
Long-term Liabilities415.4 M $64%

Key Figures

YoY change

Total Assets434.6 M $+32.8%

Total Liabilities651.7 M $-1.4%

Total Equity-217.1 M $—

Cash & ST Investments220.5 M $+103.2%

Total Debt597.4 M $-0.3%

Net Debt376.9 M $-23.2%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
IRWD	1.41	-275.1%	1.82	-50.0%
GENIL	1.33	41.0%	1.10	52.6%
ECILC	1.73	5.9%	-0.10	81.0%
HLN	0.92	52.3%	3.50	50.3%
BHC	1.32	-1,010.0%	3.71	-8.4%
TLRY	2.79	20.4%	-0.07	75.1%
Industry median	2.22	46.3%	1.24	45.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
IRWD	1.41	-275.1%	1.82	-50.0%
AMPH	3.85	88.7%	2.05	46.9%
PCRX	4.73	62.9%	1.77	54.1%
EBS	4.29	109.7%	2.68	39.6%
EOLS	2.04	-573.0%	-8.20	-13.0%
PAHC	3.17	217.6%	3.15	25.0%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow112.2 M $+42.9%

Capital Expenditures5 K $-95.9%

Free Cash Flow112.2 M $+43.1%

Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
IRWD	31.0%	31.0%	0.0%	109.8%
GENIL	6.4%	-6.7%	4.8%	162.4%
ECILC	13.9%	16.1%	7.1%	-391.0%
HLN	12.5%	11.3%	1.2%	99.0%
BHC	16.2%	11.3%	4.9%	-119.7%
TLRY	-5.6%	-8.3%	3.8%	3.5%
Industry median	15.2%	11.6%	2.5%	84.3%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
IRWD	31.0%	31.0%	0.0%	109.8%
AMPH	23.4%	18.8%	4.7%	213.2%
PCRX	19.4%	18.1%	1.3%	2,767.9%
EBS	21.9%	20.0%	1.9%	-1,720.9%
EOLS	-12.1%	-14.4%	2.3%	84.3%
PAHC	4.4%	0.9%	3.6%	69.4%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on IRWD

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.